TAFA1/FAM19A1 Antibody (492821) [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: WB
• Clone: 492821
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 594

TAFA1/FAM19A1 Antibody (492821) [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human TAFA1/FAM19A1
  Ser26-Thr133
  Accession # Q7Z5A9
• Specificity: Detects human TAFA1/FAM19A1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross‑reactivity with recombinant human TAFA2, 3, 4, or 5 is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TAFA1/FAM19A1 Antibody (492821) [Alexa Fluor® 594]

• Chemokine-like protein TAFA-1
• FAM19A1
• family with sequence similarity 19 (chemokine (C-C motif)-like), member A1
• TAFA1
• TAFA-1

Background

TAFA1 (also FAM19A1) is a secreted, 13 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 133 amino acid (aa) precursor that contains a 19 aa signal sequence and a 114 aa mature chain. Like other members of the FAM19/TAFA family, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX7CCX13CXCX14CX11CX4CX5CX10C, in which C represents a conserved cysteine residue and X represents a noncysteine amino acid (1). Human TAFA1 is 100% aa identical to mouse TAFA1. TAFA1 is expressed exclusively in the brain, with highest expression in the frontal cortex, temporal cortex, occipital cortex, parietal cortex and medulla, and low levels in the basal ganglion, thalamus, and cerebellum (1). First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1, 2). And third, TAFAs may control axonal sprouting following brain injury (1).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.